Posts

Eli Lilly Partners with Magnet Biomedicine in $1.25B Molecular Glue Deal

on

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

on

HHS Makes Musk-Directed Email Demands Voluntary, Warns of Foreign Actor Threat ##

on

Roche rolls out new DNA 'sequencing-by-expansion' approach

on

Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff

on

Eikon pulls in $351M as lead drug begins Phase III journey

on

Grey's Anatomy Star Kate Walsh Partners with GRAIL for Multi-Cancer Early Detection Awareness Campaign

on

FDA updates Boston Scientific's Accolade pacemaker recall, reporting 832 injuries

on

5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch

on

Hims eyes growth in its weight loss business, despite end of semaglutide shortage

on

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

on

Lava cuts jobs by 30% after key drug discontinued

on

Eli Lilly Acquires Organovo's FXR Program for $10M, Triggering 244% Stock Surge

on

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field

on

Lilly lowers price of Zepbound vials, launches new doses

on

Eli Lilly makes Zepbound vials cheaper for self-paying patients

on

Repare axes 75% of staff as it hunkers down on two early stage assets

on

Ryvu cuts headcount by 30%, narrows Phase II strategy to three trials

on

FDA Moves to Rehire Some Recently Fired Employees Amid Backlash

on

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech's IPO Plans

on

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

on

Compounders Sue FDA Over Removal of Semaglutide from Drug Shortage List

on

Takeda fronts $46M for 2nd small molecule collab with BridGene

on

BioCity's SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease

on

Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss

on

Ex-CDER chief Patrizia Cavazzoni becomes Pfizers chief medical officer

on

Amgen expands Indian footprint with $200M tech hub

on

Entrada given go-ahead to test DMD therapy after two-year hold

on

Pfizer taps former FDA drug chief Cavazzoni as new CMO

on

FDA Approves Label Changes for Indivior's Sublocade, Enhancing Treatment Accessibility for Opioid Use Disorder

on

AstraZeneca to acquire FibroGen's China unit for $160M

on

FDA Lifts Clinical Hold on Entrada's Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years

on